1Laufs U,Fata VL,Pluteky J,et al.Upregulation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors.Circulation,1998,97:1129
2Krone W,Muller WD.Lipid lowering therapy and stabilization of atherosclerotic plaques.Thromb-Haemost,1999,82(suppl.1):60
3Haffner SM,Lehto S,Ronneman T,et al.Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction.N Engl J Med,1998,339:229
5Ground SM, Cleeman JI, Merz CN, et al. Implication of recnt clinical trials for the National Cholosterol Education program Adutt Treatment panel Ⅲ Guidelines[J]. Am Coil Cardiol,2004,44(3) :720.
6ROSENSON RS. Pluripotential mechanisms of cardioprotection with HM G2CoA reductase inhibitor thercopy [ J ]. Am J Cardiovasc Orugs,2001,1(6) :411 -420.
7Ichiki T,Takedu K,Tokunon T,et al. Downregulation of angio-tensin Ⅱ type 1 receptor by hydorophobic 3-hydrosy 3-methylglutar-yl coenxyme A reductase inhibitors in vascular smooth muscle cell[ J]. Arterioscler Thromb Vasc Biol,2001,21 (12) :1896 - 1901.
